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Abstract
Anaplastic thyroid carcinoma (ATC) is a very aggressive thyroid cancer. forkhead box protein M1
(FOXM1) is a member of the forkhead box family of transcription factors involved in control of
cell proliferation, chromosomal stability, angiogenesis, and invasion. Here, we show that FOXM1
is significantly increased in ATCs compared with normal thyroid, well-differentiated thyroid
carcinomas (papillary and/or follicular), and poorly differentiated thyroid carcinomas
(P=0.000002). Upregulation of FOXM1 levels in ATC cells was mechanistically linked to loss-of-
function of p53 and to the hyperactivation of the phosphatidylinositol-3-kinase/AKT/FOXO3a
pathway. Knockdown of FOXM1 by RNA interference inhibited cell proliferation by arresting
cells in G2/M and reduced cell invasion and motility. This phenotype was associated with
decreased expression of FOXM1 target genes, like cyclin B1 (CCNB1), polo-like kinase 1
(PLK1), Aurora B (AURKB), S-phase kinase-associated protein 2 (SKP2), and plasminogen
activator, urokinase: uPA (PLAU). Pharmacological inhibition of FOXM1 in an orthotopic mouse
model of ATC reduced tumor burden and metastasization. All together, these findings suggest that
FOXM1 represents an important player in thyroid cancer progression to the anaplastic phenotype
and a potential therapeutic target for this fatal cancer.
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Introduction
Anaplastic thyroid carcinoma (ATC) is a rare tumor that accounts for 2–5% of all thyroid
cancers. ATC ranks among the most lethal solid malignancies with a mean survival rate of
4–12 months after diagnosis. ATC usually presents between the 6th and the 7th decade of
life as a rapidly enlarging neck mass that extends locally and disseminates to regional nodes
and distant sites. Multimodal therapy, including surgery, chemotherapy, and radiotherapy,
has only limited benefits in the locoregional control of the disease (Kondo et al. 2006,
Smallridge et al. 2009).
ATCs share genetic alterations with well-differentiated thyroid carcinoma (WDTC; papillary
thyroid carcinoma (PTC) or follicular thyroid carcinoma (FTC)) and poorly differentiated
thyroid carcinoma (PDC), namely point mutations in RAS and BRAF (Garcia-Rostan et al.
2003, Nikiforova et al. 2003). Activation of the phosphatidylinositol-3-kinase (PI3K)
pathway, with point mutation or gene amplification of PIK3CA or AKT and loss of PTEN,
is more frequently found in ATCs than in WDTCs (Gimm et al. 2000,Frisk et al. 2002,
Garcia-Rostan et al. 2005, Wu et al. 2005, Santarpia et al. 2008, Ricarte-Filho et al. 2009,
Saji & Ringel 2010). Accordingly, intercross of transgenic mice expressing oncogenic Ras
with Pten null mice gave rise to highly aggressive ATCs (Miller et al. 2009). Moreover,
while WDTCs are rarely associated with Tp53 mutation, ATCs feature Tp53 mutations (67–
88%) or dysfunction (Kondo et al. 2006, Smallridge et al. 2009, Nikiforov & Nikiforova
2011).
At a variance from WDTC, ATC has a high proliferation rate and marked aneuploidy
(Wreesmann et al. 2002). Recently, we identified a gene expression signature associated
with this ATC phenotype (Salvatore et al. 2007). This signature included upregulation of
forkhead box protein M1 (FOXM1).
FOXM1 is a member of the forkhead box family of transcription factors (Korver et al.
1997). It promotes cell cycle progression by affecting both the G1/S and the G2/M
transitions, and it is an important regulator of chromosomal stability (Laoukili et al. 2005).
Accordingly, FOXM1 regulates the expression of a large number of G2/M-specific genes,
such as cyclin B1 (CCNB1), polo-like kinase 1 (PLK1), never in mitosis gene-related kinase
2 (NEK2), and centromere protein F (CENPF). Interestingly, most of these genes were part
of the ATC signature (Salvatore et al. 2007) and one of them, PLK1, was shown to be a
promising therapeutic target for ATC (Nappi et al. 2009). FOXM1 deletion is associated
with mitotic spindle defects and cell death through mitotic catastrophe (Wonsey & Follettie
2005). Compounds, like the antibiotic thiostrepton, targeting FOXM1 induce apoptosis in
cancer cell lines, suggesting that FOXM1 may represent a potential therapeutic cancer target
(Bhat et al. 2009, Hegde et al. 2011). FOXM1 has also been shown to regulate the
transcription of genes involved in angiogenesis and invasion, thus acting as a master
regulator of metastasization (Raychaudhuri & Park 2011). Accordingly, FOXM1
downregulation reduced invasion and migration of pancreatic and breast cancer-derived cell
lines (Wang et al. 2007, Ahmad et al. 2010). FOXM1 overexpression has been observed in
several human cancers, including glioblastoma (Liu et al. 2006), basal cell (Teh et al. 2002),
hepatocellular (Kalinichenko et al. 2004), breast (Wonsey & Follettie 2005), prostate (Kalin
et al. 2006), and gastric (Li et al. 2009) carcinomas, being frequently associated with high
proliferative rates, invasive phenotype, and dismal prognosis.
Recently, Ahmed et al. (2012) reported that FOXM1 was upregulated in a fraction (28.4%)
of PTCs. Moreover, chemical or genetic FOXM1 block reduced PTC cell invasiveness,
survival, and metalloproteinase (MMP2 and MMP9) expression levels.
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Here, we show that FOXM1 is strongly upregulated in ATCs. We also show that FOXM1
expression in ATC cells is sustained by the PI3K/AKT as well as by the loss-of-function of
the p53 pathway. FOXM1 knockdown reduced proliferation, survival, and invasion of ATC
cells. Finally, pharmacological inhibition of FOXM1 reduced tumor burden and
metastasization in an orthotopic mouse model of ATC. These results suggest that ATC cells
are addicted to FOXM1 and that FOXM1 targeting may represent a strategy for the
treatment of ATCs.
Materials and methods
Tissue samples and immunohistochemistry
Formalin-fixed paraffin-embedded ATC, PDC, and normal thyroid tissue samples (132
cases and 552 tissue cores) for immunohistochemical analysis were retrieved from the files
of the Pathology Departments of Hospital Central de Asturias (Oviedo University, Asturias,
Spain) and Hospital Clinico Universitario Santiago Compostela (Santiago de Compostela
University, Galicia, Spain). An additional group of WDTC (36 PTCs and ten FTCs) tissue
samples were retrieved from the files of the Department of Surgery, University of Pisa
(Italy). Processing of samples and patient information proceeded in agreement with review
board approved protocols. Case selection was based on the histological findings and
availability of adequate material for RNA extraction. All histological diagnoses were
reviewed by two blinded pathologists (G Garcia-Rostan and C Ugolini) according to the
latest recommendations about diagnostic features of PTC, FTC, PDC, and ATC (Hedinger et
al. 1989, Volante et al. 2007, Garcia-Rostan & Sobrinho-Simoes 2011). Twenty-seven
percent of the PDCs (21/78) analyzed disclosed intratumoral progression, with concurrent
WDTC areas (PTC or FTC in 19 or two samples respectively). Twenty-four percent (24.4%)
of the ATCs (10/41) featured concurrent PDC (four cases), PTC (three cases), FTC (one
case), or PDC and PTC (two cases) areas. Whenever observed, such areas with different
degree of differentiation and/or aggressiveness within the same case were individually
analyzed. Formalin-fixed and paraffin-embedded 3–5 μm-thick tissue microarray (TMA)
sections were deparaffinized, placed in a solution of absolute methanol and 0.3% hydrogen
peroxide for 30 min, and treated with blocking serum for 20 min. The slides were incubated
with rabbit polyclonal anti-FOXM1 antibody (dilution 1:200; H-300, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and processed according to standard procedures.
Negative controls by omitting the primary antibody were included. To improve the
representativity of the expression analysis, two to six core biopsies of 1 mm in diameter,
from different regions of the same specimen or different blocks of the same tumor, were
included in the TMAs. Cases were scored as positive when unequivocal brown staining was
observed in the nuclei of tumor cells. Immunoreactivity was expressed as the average
percentage of positively stained target cells (—: no staining, <5% positive cells; +: low/
weak, ≥5–≤25% positive cells; ++: medium/moderate, >25–<50% positive cells; +++: high/
strong, ≥50 positive cells). Score values were independently assigned by two blinded
investigators (G Garcia-Rostan and C Ugolini) and a consensus was reached on all scores
used for computation.
RNA extraction and RT-PCR
Snap-frozen thyroid tumors and normal thyroid (from patients who underwent neck
dissection for other diseases) tissue samples (61 cases) for RNA extraction and RT-PCR
were retrieved from the files of the Department of Surgery, University of Pisa (Italy). RNA
was isolated using’ the RNeasy Kit (Qiagen). The quality of the RNAs was verified by the
2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany); only samples with RNA
integrity number value >7 were used for further analysis. RNA (1 μg) from each sample was
reverse transcribed with the QuantiTect Reverse Transcription (Qiagen). PCR reactions were
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done in triplicate and fold changes were calculated with the formula:
2—(sample 1 ΔCt—sample 2 ΔCt), where ΔCt is the difference between the amplification
fluorescent threshold of the mRNA of interest and the mRNA of RNA polymerase 2 used as
an internal reference. Primers and PCR conditions are listed in Supplementary Materials and
Methods, see section on supplementary data given at the end of this article.
Cell cultures
Normal thyroid P5 cells were provided by F Curcio (Università di Udine, Udine, Italy) in
2003. All the other cell lines are derived from primary ATCs. 8505C and CAL62 cells were
purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)
GmbH, Braunschweig, Germany) in 2006. HTH74 cells were obtained from N E Heldin
(University Hospital, Uppsala, Sweden) in 2005. OCUT-2, TTA1, and ACT1 cells were
provided by N Onoda (Osaka University of Medicine, Osaka, Japan) in 2005. All the cells
were DNA profiled by short tandem repeat analysis and shown to be unique and identical to
those reported in Schweppe et al. (2008). P5 were grown as described previously (Curcio et
al. 1994). The thyroid cancer cell lines were grown in DMEM (Invitrogen) containing 10%
fetal bovine serum. LY294002 was from Calbiochem (Merck Chemicals Ltd.) and used at
10 μM final concentration. PD98059 was from Cell Signaling (Beverly, MA, USA) and
used at 50 μM final concentration. Thiostrepton was from Sigma–Aldrich.
Protein studies
Protein extraction and immunoblotting was carried out according to standard procedures.
Anti-FOXM1 antibody (H-300) was from Santa Cruz Biotechnology; anti-cleaved (Asp175)
caspase-3 was from Cell Signaling; anti-poly(ADP-ribose) polymerase (anti-PARP)
monoclonal antibody, which detects full-length PARP and the large fragment (89 kDa)
produced by caspase cleavage, was from BD Biosciences (San Jose, CA, USA); monoclonal
anti-α-tubulin was from Sigma–Aldrich. Secondary anti-mouse and anti-rabbit antibodies
coupled to HRP were from Santa Cruz Biotechnology.
Plasmids
The HA-FOXM1b plasmid was purchased from Origene Technologies (Rockville, MD,
USA); HA-FOXM1c was a kind gift of Dr K M Yao (University of Hong Kong). Expression
vectors for wild-type p53, p53-R248G, p21(CIP1/WAF1) (CDKN1A), E2F1 (1–374), E2F4,
wild-type AKT, AKT-K179M, and FOXO3a were used.
RNA interference
FOXM1 siRNA smart pool was purchased from Dharmacon (Lafayette, CO, USA). The
siCONTROL non-targeting pool (#D-001206-13-05) was used as a negative control. Cells
were transfected with 100 nM siRNA using Dharmafect 3 siRNA reagent following
manufacturer’s instructions.
Invasion assay
In vitro invasiveness through Matrigel was assayed using transwell cell culture chambers.
Briefly, 8505C and HTH74 confluent cell monolayers were harvested with trypsin/EDTA
and centrifuged at 800 g for 10 min. The cell suspension (1×105 cells/well) was added to the
upper chamber of transwells on prehydrated polycarbonate membrane filter of 8 μm pore
size (Costar, Cambridge, MA, USA) coated with 35 μg Matrigel (BD Biosciences). The
lower chamber was filled with complete medium. Cell dishes were incubated at 37 °C in 5%
CO2 and 95% air for 24 h. Nonmigrating cells on the upper side of the filter were wiped-off
and migrating cells on the reverse side of the filter were stained with 0.1% crystal violet in
20% methanol for 15 min, counted, and photographed. Cell migration was quantified by
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counting the number of stained nuclei in five individual fields in each transwell membrane
in triplicate. Each experiment was repeated three times.
Wound healing assay
8505C and HTH74 cells were grown up to 80% confluence; a wound of ~300 μm width was
inflicted to the cell monolayer with a sterile pipette tip. The culture medium was changed to
remove nonadherent cells. The progress of wound closure (healing) was monitored and
microphotographs of ×10 magnification were taken immediately and 24 h after the wound.
Pixel densities in the wound areas were measured using the Cella Software (Olympus
Biosystem GmbH, Hamburg, Germany) and expressed as percentage of wound closure. The
experiment was repeated three times.
Luciferase assay
Cells were transfected with 500 ng of the reporter plasmid DNA (6XCDX2), together with
the other required plasmids, using Lipofectamine reagent (Invitrogen) according to
manufacturer’s instructions. A plasmid expressing the enzyme Renilla luciferase (pRL-null)
was used as internal control. In all cases, the total amount of transfected plasmid DNA was
normalized by adding empty vector DNA. Forty-eight hours after transfection, Firefly and
Renilla luciferase activities were assayed using the Dual-Luciferase Reporter System
(Promega Corporation), and the Lumat LB9507 luminometer (EG Berthold, Bad Wildbad,
Germany). Each experiment was done in triplicate.
Fluorescence-activated cell sorter analysis
Cells were harvested and fixed in 70% ethanol for 4 h. After washing with PBS, cells were
treated with RNase A (100 units/ml) and stained with propidium iodide (25 μg/ml; Sigma–
Aldrich) for 30 min. Samples were analyzed with an FACS-CyAN interfaced with the
Summit V4.2 Software (Dako, Glostrup, Denmark). Data were analyzed with the Modfit
Software (Verity Software House, Topsham, ME, USA).
Orthotopic tumor experiments
Mice experiments were done in the Division of Cancer Biology and Angiogenesis (Program:
Human Thyroid Cancers Preclinical and Translational Research) at the Beth Israel
Deaconess Medical Center (Boston, MA) in accordance with federal, local, and institutional
guidelines. We used an orthotopic mouse model of ATC as described previously (Nucera et
al. 2009, 2010,2011). Eight mice (4- to 6-week-old severe combined immunodeficient –
SCID ICR – female mice, Taconic, USA) were injected in the right mouse thyroid lobe with
8505c ATC cells and randomly divided into two groups (vehicle or thiostrepton) of four
mice each. Thiostrepton was dissolved at a concentration of 50 mg/ml in 1% dimethyl
sulfoxide (DMSO) in PBS and the drug solution was sonicated for 10 min. Mice were
treated by i.p. injection with 500 mg/kg body weight per day of thiostrepton or with vehicle
using a Hamilton syringe, twice a week for 3 weeks starting 7 days after orthotopic tumor
implantation (early therapeutic intervention model). Thiostrepton-treated mice compared to
vehicle-treated mice displayed signs of toxicity in the third week of treatment (e.g. 1.2-fold
decrease in body weight and piloerection). Mice were killed and tissue specimens were fixed
with 10% buffered formalin phosphate and embedded in paraffin blocks. Histopathology
evaluation was performed by an endocrine pathologist (PM Sadow, MGH, Harvard Medical
School, Boston) on hematoxylin and eosin (H&E)-stained tissue sections of the orthotopic
thyroid tumors, the surrounding perithyroidal tissues, and the lungs. Slides were examined
with an Olympus BX41 microscope and the Olympus Q COLOR 5 photo camera (Olympus,
Center Valley, PA, USA). For each mouse, the number of metastases was counted as the
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number of pleomorphic 8505c cells foci/section of whole lung. The number of metastases
found in each mouse was averaged per each group.
Statistical analysis
The two-tailed unpaired Student’s t-test was used for statistical analysis. All P values were
two sided and differences were significant when P was <0.05. All statistical analysis was
carried out using the GraphPad Instat Software program (version 3.06.3; GraphPad, San
Diego, CA, USA).
Results
Increased FOXM1 expression in ATC
We studied the expression of FOXM1 by immunohistochemistry in a set of 13 normal
thyroids, 78 PDCs, and 41 ATCs. Results are reported in Table 1 and representative pictures
are shown in Fig. 1. FOXM1 was not detectable in normal thyroid samples. Overall, 45 and
90% of the PDCs and ATCs respectively expressed FOXM1 (P=0.0000011 two-tailed
Fisher’s exact test; relative risk (RR)=0.16; 95% confidence interval (95% CI), 0.063–
0.434). High (+++) and/or medium (++) levels of FOXM1 immunoreactivity significantly
correlated with the ATC phenotype (17 vs 65% of positively stained PDCs and ATCs
respectively; P=0.000045 Fisher’s exact test; χ2 Yates value 14.95, P=0.00011 and χ2
Pearson value 16.85, P<0.0001; RR=2.58; 95% CI, 1.59–4.20; Table 1 and Fig. 1). In a very
small set of distant metastases of PDC cases to the brain or lung (three cases), we observed
that those metastases that exhibited a PDC phenotype expressed FOXM1 (30–50% of the
cells) while the metastasis displaying a phenotype (FTC) that was better differentiated than
the primary tumor (PDC) was negative for FOXM1 (Supplementary Figure 1, see section on
supplementary data given at the end of this article).
Thirty-one out of 119 PDC and ATC cases presented concurrent areas displaying more
prominent differentiated features than the rest of the tumor (see Table 2). In 11 (35.5%) of
these cases, FOXM1 expression was restricted to the PDC or ATC areas (Table 2). Twenty-
one percent (5/24) of the concurrent PTC foci present in the PDCs and ATCs analyzed
displayed low immunoreactivity (≥5–≤25% positive cells) and none showed moderate or
high staining levels (Table 2). This figure is consistent with a recent report by Ahmed et al.
(2012), who reported FOXM1 expression in 28.4% of PTC. Finally, none of the concurrent
FTC foci (n. 3) present in the PDCs and ATCs analyzed expressed FOXM1.
Then, we selected a group of additional WDTCs (FTCs and PTCs) for further analysis. In
particular, we selected PTCs belonging to different subtypes and that have infiltrated or not
tumor or thyroid capsule. As shown in Supplementary (Table 1), see section on
supplementary data given at the end of this article, both FTCs and PTCs resulted negative or
disclosed low (+) FOXM1 expression levels. PTC stain for FOXM1 depended on the
specific variant analyzed. According to Ahmed et al. (2012), tall-cell variant PTC as well as
PTCs with tall-cell areas featured increased positivity compared with the other PTC variants
(P=0.027 Fisher’s exact test; χ2 Yates value 4.71, P=0.029 and χ2 Pearson value 6.41,
P=0.011; RR=1.77; 95% CI, 1.08–2.90). Moreover, a significant correlation was found
between FOXM1 expression and tumor (P=0.017 Fisher’s exact test) or thyroid (P=0.0045
Fisher’s exact test; χ2 Yates value 7.71, P=0.005 and χ2 Pearson value 9.75, P=0.001;
RR=2.28; 95% CI, 1.25–4.17) capsule invasion. Instead, no correlation was found between
FOXM1 expression and the presence of lymph node metastases from primary PTCs (P=0.30
Fisher’s exact test; Supplementary Table 2, see section on supplementary data given at the
end of this article). Even when considering selected cases of WDTCs (with a high
percentage of infiltrating tumors), we observed that FOXM1 was significantly increased in
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ATCs compared with WDTCs (PTCs+FTCs; P=0.000003), PTCs (P=0.0001), and FTCs
(P=0.00002).
We performed qRT-PCR analysis on RNA extracted from normal thyroids (16 cases), PTCs
(19 cases), PDC (11 cases), and ATCs (15 cases). FOXM1 mRNA expression was
significantly higher in ATC samples compared with normal thyroid (P<0.001), PTCs
(P<0.001), and PDCs (P<0.001; Fig. 2A).
FOXM1 gene is located on chromosome 12p13.3 and consists of nine exons, two of which
(A1 and A2) are alternatively spliced giving rise to three differentially expressed forms:
FOXM1a (containing both A1 and A2 exons), FOXM1c (containing only A1), and
FOXM1b (lacking both A1 and A2) (Fig. 2B). Only FOXM1b and FOXM1c are active as
transcription factors because of the lack of the inhibitory sequence encoded by exon A2 (Ye
et al. 1997). To address the relative expression of the three forms in normal and tumor
thyroid tissues (nine samples for each category), we applied RT-PCR and primers
specifically designed to amplify the regions containing A1 and A2 exons. These primers
generate large or small PCR fragments depending on the presence or not of the targeted
exon. In particular, to discriminate between FOXM1a and FOXM1b and c, we used a primer
pair (F3 and R3) that produced PCR fragments of 472 and 358 bp respectively depending on
the presence of exon A2 (variant FOXM1a); to discriminate between FOXM1b and
FOXM1a and c variants, we used primers (F2 and R2) that produced PCR fragments of 481
and 436 bp respectively depending on the presence of exon A1 (variants FOXM1a and c;
Fig. 2B). FOXM1b and FOXM1c plasmids were used to generate PCR products as
molecular weight controls. Tumor samples predominantly expressed FOXM1c (Fig. 2C).
Noteworthy, FOXM1c was reported to be the variant that more strongly triggers
proliferation and invasion of cancer cells (Kim et al. 2006). According to the qRT-PCR data,
FOXM1 expression in ATC was more prominent and consistent than in PTC and PDC.
Deregulation of the p53 and PI3K pathways promotes FOXM1 overexpression in ATC cells
We investigated mRNA and protein levels of FOXM1 in a panel of ATC cell lines. A
primary culture of normal thyrocytes, P5, was used as control. ATC cell lines expressed high
levels of FOXM1 mRNA (Fig. 3A) and protein (Fig. 3B) compared with normal cells. As
for tissue samples, ATC cell lines expressed FOXM1c form (Fig. 3A).
Then, we searched for ATC-associated molecular pathways that may trigger FOXM1
upregulation. FOXM1 has been recently identified as a target of p53-mediated repression,
secondary to p21(CIP1/-WAF1)-mediated Rb dephosphorylation and E2F downregulation
(Barsotti & Prives 2009, Pandit et al. 2009). This event is critical for the maintenance of a
stable G2 arrest in response to DNA damage. Thus, we transfected two ATC-derived cell
lines, 8505C and HTH74, both harboring TP53 point mutations (R248G and K286E
respectively) with plasmids coding for wild-type p53, p53-R248G (inactive mutant),
p21(CIP1/WAF1), E2F1(1–374) (a dominant negative E2F1), and E2F4 (a negative
regulator of the E2F family) together with a firefly luciferase reporter (6XCDX2) that
contains FOXM1 binding sites and therefore is able to monitor FOXM1 transcriptional
activity (Kim et al. 2006). As shown in Fig. 4A, adoptive overexpression of p53 wt,
p21(CIP1/WAF1), E2F1(1–374), and E2F4 decreased FOXM1 activity, compared with cells
transfected with the empty vector (P<0.001), while p53-R248G did not show any significant
effect (Fig. 4A). Consistently, FOXM1 mRNA levels, as measured by qRT-PCR, were
reduced in p53 wt-, p21(CIP1/WAF1)-, and E2F4-transfected cells (Fig. 4B).
Thyroid cancer often features constitutive activation of the PI3K/AKT pathway (Garcia-
Rostan et al. 2005,Saji & Ringel 2010) and this event is more prevalent in ATC than in
WDTC (Gimm et al. 2000, Garcia-Rostan et al. 2005, Saji & Ringel 2010). FOXO3a
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transcription factor is negatively controlled by AKT and, in turn, FOXM1 gene expression is
negatively regulated by FOXO3a in breast cancer (McGovern et al. 2009). Thus, we
transfected ATC cells with plasmids coding for a dominant negative AKT mutant (K179M),
wild-type AKT (used as a control), and FOXO3a together with the FOXM1 activity reporter.
AKT (K179M) and FOXO3a transfection strongly reduced FOXM1 activity in ATC cells,
while wild-type AKT showed no significant effect (Fig. 4A). Accordingly, treatment with
LY294002, a chemical PI3K inhibitor, reduced FOXM1-responsive reporter (Fig. 4A) and
FOXM1 mRNA levels (Fig. 4B). Importantly, chemical blockade of the MAPK pathway by
the MEK1 inhibitor PD98059 did not recapitulate this event (Fig. 4A).
Based on these findings, we correlated protein expression levels of FOXM1 with those of
p53 (an indirect marker suggestive of p53 pathway inactivation), phospho-AKT (pSer473),
and pERK (Thr202/Tyr204) by immunohistochemical stain of the ATC/PDC TMAs. In
summary, among 41 ATC samples, four scored negative and 37 scored positive for FOXM1;
one scored negative and 40 scored positive for pAKT; ten scored negative and 31 scored
positive for p53; and 26 scored negative and 15 scored positive for pERK. Among PDC
samples, 43 scored negative and 35 scored positive for FOXM1; six scored negative and 72
scored positive for pAKT; 44 scored negative and 34 scored positive for p53; and 48 scored
negative and 30 scored positive for pERK. By applying linear regression analysis, a
correlation was found between FOXM1 expression and p53 (P=0.005; Pearson correlation
coefficient (ρ) 0.254) or pAKT (P=0.0015; Pearson correlation coefficient (ρ) 0.286) stain
but not between FOXM1 and pERK (P=0.2) stain. All together, these findings suggest that
loss of p53 and gain of AKT pathways are molecular events driving FOXM1 transcription
levels in thyroid cancer.
Downregulation of FOXM1 inhibited ATC cell growth and invasion in vitro
We knocked down FOXM1 expression by siRNA in 8505C and HTH74 and monitored cell
counts in triplicate at 48 h. FOXM1 siRNA but not negative control caused growth
inhibition in both cell lines tested (P<0.001; Fig. 5A), parallel to FOXM1 mRNA
knockdown (see below Fig. 5D). This effect was associated with a reduced S phase entry
(P<0.05) as well as an accumulation of the cells in the G2 phase of the cell cycle (P<0.05) as
shown by FACS analysis (Fig. 5A).
ATC features a highly invasive and metastatic phenotype. FOXM1 promotes the
transcription of genes involved in extracellular matrix degradation and motility, thereby
acting as a master regulator of metastasization (Raychaudhuri & Park 2011). Thus, we
monitored cell motility (wound closure assay) and invasion (transwell chamber assay) upon
FOXM1 knockdown. FOXM1 depletion significantly impaired the capability of ATC cells
(8505c and HTH74) to close the wound (P<0.001; Fig. 5B) and to invade through Matrigel
(P<0.001; Fig. 5C) when compared to the scrambled control.
Finally, we tested whether pro-mitogenic and -invasive effects were mediated by the
transcriptional program induced by FOXM1. Transcriptional effects of FOXM1 include
upregulation of genes involved in cell proliferation and invasion (Laoukili et al. 2005). As
shown in Fig. 5D, FOXM1 downregulation in ATC cells blunted the expression of mRNAs
related to cell cycle as well as invasion such as CCNB1, PLK1, AURKB, SKP2, and PLAU.
Noteworthy, some of these FOXM1 targets have been previously reported to be upregulated
in ATC (SKP2, Chiappetta et al. (2007); CCNB1, Ito et al. (2002); AURKB, Sorrentino et
al. (2005) and Wiseman et al. (2007); and PLK1, Nappi et al. (2009)).
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Pharmacological inhibition of FOXM1-reduced growth and metastasization of ATC cells in
an orthotopic mouse model
FOXM1 has been recently considered as a potential therapeutic target for cancer treatment,
thanks to the discovery of a group of compounds able to bind it and inhibit its transcriptional
activity (Bhat et al. 2009). Owing to the breakage of a FOXM1-dependent positive feedback
loop, these drugs lead to FOXM1 protein reduction and cell death due to apoptosis (Halasi
& Gartel 2009). We first tested whether thiostrepton, the most characterized among them
(Radhakrishnan et al. 2006, Kwok et al. 2008, Hegde et al. 2011), was effective at reducing
FOXM1 transcriptional activity and protein level in ATC cells. As shown in Supplementary
(Figure 2), see section on supplementary data given at the end of this article, thiostrepton
treatment reduced in a dose-dependent manner FOXM1 transcriptional activity as well as its
protein levels at 48 h of treatment. Furthermore, this led to a reduction of ATC cell viability
as measured by cell count at 48 h (Supplementary Figure 2, see section on supplementary
data given at the end of this article).
Thus, we used a recently developed orthotopic mouse model of ATC (Nucera et al. 2009).
This system closely recapitulates human ATC morphology and biological behavior and
allows the study of ATC cell growth into their natural environment and their metastatic
properties. We injected 8505c cells into the right thyroid lobe of immunocompromised mice
and randomly treated them twice weekly with 500 mg/kg body weight per day of
thiostrepton or vehicle. Thiostrepton treatment dramatically reduced tumor volume (P<0.05;
Fig. 6A, B and E). Thyroid tumors in vehicle-treated mice featured a highly invasive
phenotype (Fig. 6C and D). In contrast, thyroid tumors in thiostrepton-treated mice showed
signs of necrosis and tumor atrophy (Fig. 6F and G). Importantly, while vehicle-treated mice
developed numerous metastatic foci in the lungs (Fig. 6H), mice treated with thiostrepton
lacked any evidence of lung metastases (Fig. 6I).
Discussion
FOXM1 oncogenic factor is a master regulator of a transcriptional program that includes
genes mediating cell proliferation, motility, invasion, and metastasization. In this study, we
show that FOXM1 expression is strongly upregulated in virtually all ATC samples (90%).
Recently, FOXM1 expression was reported to be negatively controlled by p53 and FOXO3a
antioncogenic transcriptional factors (Barsotti & Prives 2009, McGovern et al. 2009, Pandit
et al. 2009). Impaired activity of both these tumor suppressors is part of the molecular
features of ATC that, indeed, include p53 loss-of-function as well as PI3K/AKT gain-of-
function mutations (Smallridge et al. 2009, Saji & Ringel 2010). Here, we show that release
from p53-and FOXO3a-negative constraints contributes to FOXM1 upregulation in ATC
cells in culture and provide immunohistochemical evidence of a correlation between AKT
and p53 pathway activity and FOXM1 expression in thyroid cancer (Fig. 7). Importantly, we
show that this pathway is amenable of therapeutic targeting by PI3K chemical inhibitors,
drugs that have been recently proposed as potential therapeutic tools in preclinical models of
thyroid cancer (Jin et al. 2009, 2011, Xing 2010, Liu et al. 2011, 2012).
FOXM1c was the FOXM1 splicing variant most abundant in ATC and FOXM1c was
reported to be the form endowed with more potent mitogenic and proinvasive effects (Kim
et al. 2006). We show that ATC cells depend on FOXM1 expression for both proliferation
and in vitro motility and invasion. Accordingly, FOXM1 ablation downregulated the
expression of a set of genes that, in turn, mediates these functions. These findings support a
model whereby FOXM1 upregulation may contribute to the locally invasive, metastatic, and
mitogenic phenotype of ATC; in turn, release of ATC cells from the normal cell cycle
checkpoints may eventually facilitate chromosomal instability, a common feature of ATC
(Fig. 7). Importantly, we could validate this model in vivo by showing that treatment with
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thiostrepton, a natural compound that reduces Foxm1 transcriptional activity and protein
level (Radhakrishnan et al. 2006, Kwok et al. 2008), strongly reduced tumor burden and
abolished metastasization in a thyroid orthotopic ATC mouse model. It should be noted,
however, that thiostrepton may mediate these effects also by affecting targets other than
FOXM1. Similarly, Ahmed et al. (2012) have previously reported that thiostrepton impairs
thyroid cancer cell growth and invasion in vitro.
Our data represent an extension of the findings recently reported by Ahmed et al. (2012),
who, studying differentiated thyroid carcinomas, demonstrated that FOXM1 was
upregulated in a fraction (28.4%) of PTCs and correlated with aggressive PTC variants (tall-
cell) and expression of molecular markers of invasiveness, such as metalloproteases. Here,
we show that FOXM1 is significantly increased in ATCs compared with WDTCs (PTCs
and/or FTCs) and PDCs, and when considering only the most aggressive thyroid cancer
phenotypes (PDCs and ATCs), high and/or moderate levels of FOXM1 were significantly
associated with ATCs. Moreover, by studying a selected series of PTC with or without
tumor and/or thyroid capsule invasion, we found that FOXM1 levels correlated with a tumor
invasive phenotype.
Altogether, these findings suggest that FOXM1 is a molecular determinant of thyroid cancer
malignant phenotype and may be exploited as a molecular marker of aggressiveness as well
as a molecular target in approaches aimed at inhibiting directly its transcriptional activity or
indirectly the pathways sustaining its expression (Fig. 7).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Immunohistochemical analysis of FOXM1 expression in human thyroid tissue samples.
Representative images of normal thyroid (NT), classic variant-PTC (CL-PTC), follicular
variant-PTC (FV-PTC), PDC, and ATC biopsies stained with a rabbit polyclonal anti-
FOXM1 antibody. Whole tissue cores (left, 10×) and zoom-in of areas present within these
particular cores (center, 40× and right, 100×), illustrating the nuclear features and FOXM1
staining pattern, are shown. The NT, CL-PTC, and FV-PTC sections are negative for
FOXM1, whereas the PDC and ATC sections disclose diffuse, medium/moderate (++), and
high/ strong (+++) nuclear immunoreactivity respectively.
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Figure 2.
FOXM1 is overexpressed at the mRNA level in human anaplastic thyroid carcinoma
samples. (A) Quantitative RT-PCR showing increased FOXM1 expression in ATC (15
cases) compared with normal thyroid (16 cases), PTC (19 cases), and PDC (11 cases)
samples. Tumor expression values are reported as fold changes with respect to the average
expression in normal samples measured with ΔCt method, after normalization for RNA
polymerase 2 (***P<0.001). (B) Schematic representation of the three alternatively spliced
FOXM1 variants (a, b, and c) and the PCR primers used to detect the presence of
alternatively spliced exons A1 and A2. (C) RT-PCR to show relative expression levels of the
three FOXM1 forms in normal thyroids, PTCs, PDCs, and ATCs (nine samples for each
category). Plasmids encoding FOXM1b and FOXM1c were used as PCR templates to
generate molecular weight controls for the presence or the absence of exon A1 (primers F2/
R2) or exon A2 (primers F3/R3). Arrows indicate expected migration for PCR products
containing (variants FOXM1a and FOXM1c) or lacking (FOXM1b) exon A1 and for PCR
products containing (FOXM1a) or lacking (FOXM1b and FOXM1c) exon A2. The
molecular weight of the PCR products is shown on the right. Levels of 18S rRNA were
measured for normalization.
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Figure 3.
FOXM1 is overexpressed at the mRNA and protein level in ATC cells. (A) Semiquantitative
RT-PCR showing increased levels of FOXM1c in ATC cells compared with normal
thyrocytes (P5; see legend to Fig. 2). Levels of 18S rRNA were measured for normalization.
(B) Western blot analysis showing increased protein expression of FOXM1 in ATC cells
compared with P5 control. Tubulin was used for normalization. These results are
representative of at least three independent experiments.
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Figure 4.
FOXM1 in ATC cells is controlled by the p53 and PI3K pathways. (A) The indicated ATC
cells were co-transfected with the indicated expression vectors (or the empty vector as
control) together with 6XCDX2 containing six copies of the FOXM1 binding site fused to
firefly luciferase. Alternatively, as indicated, cells were treated for 48 h with the PI3K
inhibitor LY294002 or the MEK1 inhibitor PD98059. Cells were co-transfected with Renilla
luciferase for normalization. Normalized luciferase levels are reported as average results of
three independent experiments with bars illustrating 95% confidence intervals. Reporter
activity in empty vector-transfected cells was arbitrary set at 10 (***P<0.001). Western blot
analysis of AKT and MAPK phosphorylation after PD98059 and LY294002 treatment is
shown on the right. (B) FOXM1 mRNA expression levels were measured in the indicated
ATC cells 72 h after transfection with the indicated plasmids or treatment with LY294002.
The average results of three independent experiments are reported together with 95%
confidence intervals. FOXM1 expression in mock-transfected cells was arbitrary set at 1.0
(***P<0.001).
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Figure 5.
Effect of FOXM1 silencing on ATC cell growth, migration, and invasion. (A) ATC cells
were transfected with either FOXM1 siRNA or the negative control siRNA or left
untransfected. Cells were harvested at 48 h and counted. Values represent the average of
triplicate experiments with bars indicating 95% confidence intervals (***P<0.001). FACS
analysis of siFOXM1 or negative control (siSCR)-transfected 8505c and HTH74 cells is
shown together with the mean percentage of cells in G1, S, and G2/M cell cycle phases.
Values represent the average of triplicate experiments (*P<0.05). (B) 8505C and HTH74
cells, transfected with either FOXM1 siRNA or the negative control, were plated at
confluence and scratch wounds were inflicted. Cell plates were photographed immediately
after wound incision and 24 h later. Photographs were taken at 10× magnification. Pixel
densities in the wound areas were measured and expressed as percentage of wound closure,
where 100% is the value obtained at 10 h for control cells. The average results of three
experiments are reported with bars representing 95% confidence intervals (***P<0.001). (C)
8505C and HTH74 cells, transfected with either FOXM1 siRNA or the negative control,
were plated in transwells coated with Matrigel. Migration through Matrigel was measured
by staining migrated cells with Giemsa. The average results of three experiments are
reported with bars representing 95% confidence intervals (***P<0.001). D) RNA was
extracted from 8505C cells, transfected with either FOXM1 siRNA or the negative control,
and quantitative RT-PCR assays were performed to detect expression levels of the indicated
mRNAs. Levels of actin were measured for normalization.
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Figure 6.
Thiostrepton treatment reduces ATC cell growth and metastasization in vivo. Eight mice
were injected orthotopically in the right thyroid lobe with 8505c cells and randomly divided
in two groups. Starting 7 days after orthotopic tumor implantation, mice were treated by i.p.
injection of thiostrepton or vehicle twice a week for 3 weeks. (A) Thiostrepton-treated mice
showed a significant decrease in thyroid tumor volume (18.5±6.8 mm3) compared with
control mice (100±19.9 mm3) (*P<0.05). (B, C, D, E, F and G) Gross and H&E
representative images of thyroids from thiostrepton-treated (E, F and G) or control (B, C and
D) mice. In control mice, aggressive ATC (arrow) infiltrating residual thyroid follicles (T),
with extra-thyroid extension into skeletal muscle (asterisk) and tracheal cartilage
(arrowhead), are visible. In thiostrepton-treated mice, tumors were smaller and round shaped
and had histological evidence of atrophy (arrowheads), intratracheal necrosis, and
peritracheal fibrosis (asterisks). (H and I) H&E images of lung metastases. In control mice
(H), eight to ten pleomorphic cell foci/lung sections (arrows) were counted. In thiostrepton-
treated mice (I), no apparent lung metastasis was detected (asterisk: bronchus).
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Figure 7.
A model for FOXM1’s role in thyroid cancer. Schematic representation of the molecular
pathways linked to FOXM1 upregulation in ATC (+ and − refer to activating or inhibitory
signals respectively) and gene targets whose expression is stimulated by FOXM1. This
pathway can be therapeutically targeted at multiple levels; as shown here and in Ahmed et
al. (2012), these levels include FOXM1 itself (thiostrepton) and PI3K (LY294002).
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Table 1
FOXM1 expression by immunohistochemistry in poorly differentiated thyroid carcinoma (PDC) and
anaplastic thyroid carcinoma (ATC)
Number of cases in each category (percentage of stained target cells)
Sample diagnosis Negative ( − ) Low/weak (+)
Medium/moderate
(++) High/strong (+++)
Normal thyroid (13 cases) 13 (100%) 0 (0%) 0 (0%) 0 (0%)
PDC (78 cases-347 cores)a 43 (55.1%) 29 (37.2%) 6 (7.7%) 0 (0%)
ATC (41 cases-192 cores)a 4 (9.7%) 13 (31.7%) 12 (29.3%) 12 (29.3%)
−, <5% of cells positive for nuclear FOXM1 expression; +, ≥5–≤25% of cells positive for nuclear FOXM1 expression; ++, >25–<50% of cells
positive for nuclear FOXM1 expression; +++, ≥50% of cells positive for nuclear FOXM1 expression.
a
To improve the representativity of the expression analysis, two to six core biopsies of 1 mm in diameter, from different regions of the same
specimen or different blocks of the same tumor, were included in the TMAs.
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Table 2
FOXM1 expression in concurrent differentiated thyroid carcinoma foci present within PDCs and ATCs
FOXM1 staining scorea
Patient number Concurrent WDTC component Prevailing PDC/ATC component
1 (−) FV-PTC (−) PDC
2 (−) FV-PTC (−) PDC
3 (−) FV-PTC (+)PDC
4 (+) CL-PTC (+)PDC
5 (+) FV-PTC (+)PDC
6 (−) FTC (+)PDC
7 (−) FV-PTC (−) PDC
8 (−) CL-PTC with focal tall-cell features (−) PDC
9 (−) FV-PTC (−) PDC
10 (−) TCV-PTC (−) PDC
11 (−) FV-PTC (+)PDC
12 (−) FTC Hürthle (+)PDC
13 (−) FV-PTC (−) PDC
14 (−) Solid PTC (+)PDC
15 (−) FV-PTC (−) PDC
16 (C ) Mixed-PTC with focal tall-cell features (+)PDC
17 (−) CL-PTC with focal tall-cell features (+)PDC
18 (−) Solid PTC (−) PDC
19 (−) FV-PTC (−) PDC
20 (−) FV-PTC (−) PDC
21 (−) FV-PTC (−) PDC
22 (−) FV-PTC      (−) PDC (+) ATC
23 (−) FV-PTC      (−) PDC (+) ATC
24 (+) PDC (+) ATC
25 (+) PDC (+) ATC
26 (+) TCV-PTC progressing to PDC (+) ATC
27 (−) FV-PTC (+++) ATC
28 (−) PDC (++) ATC
29 (+) FV-PTC (+++) ATC
30 (−) FTC Hürthle (+++) ATC
31 (++) PDC (++) ATC
The concurrent better differentiated thyroid carcinoma components present within poorly differentiated thyroid carcinomas (PDCs) and anaplastic
thyroid carcinomas (ATCs) included well-differentiated follicular thyroid carcinoma (FTC), follicular variant of papillary thyroid carcinoma (FV-
PTC), classic papillary thyroid carcinoma (CL-PTC), mixed papillary thyroid carcinoma (FV-PTC+CL-PTC), solid PTC, and tall-cell variant of
PTC (TCV-PTC).
aScore is reported as in Table 1.
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